Stockreport

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with ad [Read more]